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PRIRATE 2020 guidelines for reporting randomized trials in Endodontics: a 




In evidence-based healthcare, randomized clinical trials provide the most accurate 
and reliable information on the effectiveness of an intervention. This project aimed 
to develop reporting guidelines, exclusively for randomized clinical trials in the 
dental specialty of Endodontology, using a well-documented, validated consensus-
based methodology. The guidelines have been named: Preferred Reporting Items for 
RAndomized Trials in Endodontics (PRIRATE) 2020. A total of eight individuals (PD, 
VN, HD, LB, TK, JJ, EP, SP), including the project leaders (PD, VN) formed a steering 
committee. The committee developed a checklist based on the items in the 
Consolidated Standards for Reporting Trials (CONSORT) guidelines and Clinical and 
Laboratory Images in Publications (CLIP) principles. A PRIRATE Delphi Group (PDG) 
and PRIRATE Face-to-Face Meeting group (PFMG) were also formed. Thirty PDG 
members participated in the online Delphi process and achieved consensus on the 
checklist items and flowchart that make up the PRIRATE guidelines. The guidelines 
were discussed at a meeting of the PFMG at the 19th European Society of 
Endodontology (ESE) Biennial congress, held on 13th September 2019 in Vienna, 
Austria. A total of 21 individuals from across the globe and four steering committee 
members (PD, VN, HD, LB) attended the meeting. As a consequence of the discussions, 
the guidelines were modified and then piloted by several authors whilst writing a 
manuscript. The PRIRATE 2020 guidelines contain a checklist consisting of 11 
sections and 58 individual items as well as a flowchart, considered essential for 








Evidence-based dentistry is an approach to oral healthcare that requires judicious 
integration of a patient's history, oral and medical condition, the dentist’s clinical 
expertise, the patient's treatment needs and preferences with systematic assessment 
of clinically relevant scientific evidence (ADA 2019). In terms of primary research 
studies, randomized clinical trials provide the highest level of evidence, because of 
their unbiased study design with minimum or no risk of systematic errors (Burns et 
al. 2011). For determining whether a cause-effect relation exists between an 
intervention and an outcome, this is the most rigorous and robust research study 
design (McCarthy 2011). However, assessment of the methodological quality of 
published randomized clinical studies in general medical subjects has highlighted 
several deficiencies, which need to be addressed (Hajibandeh et al. 2015, You et al. 
2017, Zeng et al. 2017).  Within Endodontics, the overall quality of reporting 
randomized clinical trials has been reported to be suboptimal (Lucena et al. 2016).   
 
Individual randomized clinical trials and subsequent systematic reviews of 
several trials should ideally underpin clinical decision-making with the aim of 
improving the overall management and outcome of patients seeking endodontic 
treatment. Within oral health research, guidelines to assist authors in writing papers 
has improved the overall completeness and transparency of the resultant 
manuscripts (Sarkis-Onofre et al. 2015). Considering the importance of randomized 
clinical trials in healthcare research, several evidence-based tools have been 
developed to improve their design and reporting quality. The most accepted and 
validated tool to improve the reporting quality of randomized clinical trial is the 
Consolidated Standards for Reporting Trials (CONSORT) statement. CONSORT 
consists of a 25-item checklist, which assists authors when preparing the reports of 
trials, facilitating their complete and transparent reporting, as well as aiding in their 
critical appraisal and interpretation (Schulz et al. 2010, Moher et al. 2010a). Since the 
introduction of the CONSORT statement, many journals, including several Endodontic 
journals, have endorsed its recommendations for reporting clinical trials.  
 
Due to the nature of endodontic treatments, in addition to reporting the 
individual components of a randomized clinical trial, in many trials it is also 
important to provide information on the associated images (radiographic, 
histological, photographic, composite figures) in an appropriate and comprehensive 
manner. The Clinical and Laboratory Images in Publications (CLIP) principles were 
developed to improve the accuracy, validity, completeness, interpretation and 
implications of images appearing in scientific articles (Lang et al. 2012).  
 
Several guidelines have been developed for individual clinical specialties by a 
modification of the original CONSORT statement, e.g. infertility treatments (Harbin 
Consensus Conference Workshop Group 2014), and acupuncture (MacPherson et al. 
2010). The CONSORT statement covers the majority of the important parameters that 
are required for reporting randomized clinical trials in Endodontics but several items 
such as a list of keywords, the strength of the trial, the conclusion, the implications of 
the work on future research and clinical practice as well as the quality of images are 
absent. As the addition of these items would conceivably improve the quality of 
manuscripts reporting clinical trials in Endodontics, there is a need to develop new 
reporting guidelines specifically designed for the discipline.  
The Preferred Reporting Items for RAndomized Trials in Endodontics 
(PRIRATE 2020) guidelines, have been developed by modifying and integrating the 
CONSORT guidelines (Moher et al. 2010a) and CLIP principles (Lang et al. 2012) 
specifically for Endodontics. The guidelines have been developed to help authors 
improve the overall reporting quality of randomized clinical trials, and thus enhance 
clinical decision-making.  The aim of this project was thus to develop the PRIRATE 
guidelines for reporting randomized clinical trials in the specialty of Endodontics 





The study design was approved by the Institutional Review Board on Research and 
Ethics of the International Medical University (IMU), Kuala Lumpur, Malaysia (No: 
IMU 450/2019). The protocol for the development of the PRIRATE guidelines is based 
on the Guidance for Developers of Health Research Reporting Guidelines (Moher et 
al. 2010b) and is explained in a previous publication (Nagendrababu et al. 2019).  
 
The phases involved in developing the PRIRATE 2020 guidelines were: 
 
Initial steps 
The project leaders (VN, PD) identified the need for guidelines for reporting 
randomized clinical trials in Endodontics. Following this, a steering committee (SC) 
consisting of eight members, including the project leaders, was formed (PD, VN, HD, 
LB, TK, JJ, EP, SP). The steering committee developed a preliminary draft checklist of 
the PRIRATE guidelines by adapting and integrating the CONSORT statements (Schulz 
et al. 2010, Moher et al. 2010a) and CLIP principles (Lang et al. 2012) to fit the 
specialty of Endodontology. The draft checklist was subjected to an online Delphi 
process to build consensus on the items of the checklist and an accompanying flow-
chart. 
 
Online Delphi process 
A PRIRATE Delphi Group (PDG) was created by the steering committee, comprising 
of 30 members including 22 academics or researchers, four clinical endodontists, two 
general dental practitioners (GDPs) and two members of the public. The academic 
and clinical members fulfilled at least one of the following eligibility criteria: 
published at least one randomized clinical trial in Endodontics; published any 
reporting guidelines for in vitro/in vivo research; a minimum 15 years of academic or 
clinical experience as an endodontist or GDP. The steering committee identified 
individuals based on the eligibility criteria and invited 30 individuals from around the 
globe to participate in the online Delphi process. The bespoke invitation letter 
explained the need for reporting guidelines for randomized clinical trials in 
Endodontics, and went on to describe the Delphi process and the role of the PDG 
members.  
 
Once confirmation of their participation was received, a Delphi document was 
shared with the PDG. This document explained the need for PRIRATE guidelines, and 
contained the draft PRIRATE checklist and flowchart along with a description of the 
online Delphi survey that explained the criteria and scoring method for including or 
excluding items from the checklist. The members of the PDG evaluated each item of 
the draft PRIRATE checklist on its suitability and clarity and scored the individual 
items on whether they were clear (‘yes’ or ‘no’) and whether the item should be 
included using a 9-point rating Likert scale (1 = ‘definitely not include’ to 9 = 
‘definitely include’). Furthermore, members were given the opportunity to provide 
their views and comments on the wording and their understanding of each item 
(Maher et al. 2015). All the items included in the checklist had to receive a score 
between 7 and 9 by ≥70% of members and between 1 to 3 by ≤30% of members. 
Similarly, items were excluded from the PRIRATE checklist if ≥ 70% PDG members 
scored an item between 1 and 3, and ≤ 30% members scored it between 7 and 9. Items 
that needed modification after the first round based on the feedback were re-scored 
by the PDG members in the second round of the Delphi process. A summary of 
anonymized results of the Delphi process and scores were shared with PDG members 
at the end of each Delphi round. The Delphi process continued until a consensus was 
reached on all the items and a final set of items was agreed by all PDG members (Agha 
et al. 2017). The revised PRIRATE checklist and flowchart created by the online 
Delphi process was thereafter discussed during the PRIRATE Face-to-Face Meeting.  
 
Face-to-Face meeting  
The PRIRATE Face-to-Face Meeting group (PFMG) included 21 individuals. The 
eligibility criteria for PFMG members were the same as those of the PDG with several 
individuals being members of both groups. The details of the venue, date and time of 
the Face-to-Face meeting were shared with the PFMG members. The Face-to-Face 
meeting was conducted on 13th September 2019 at the 19th European Society of 
Endodontology (ESE) biennial congress held in Vienna, Austria. The results of the 
online Delphi study, the checklist along with the flowchart, and the agenda were 
shared prior to the meeting. In the meeting, the project leaders (PD, VN) presented 
the results of the Delphi process, the rationale for including the checklist items and 
flow chart in the PRIRATE guidelines, prior to leading a discussion that debated the 
items and flowchart. 
 
Post-meeting activities 
A final list of the PRIRATE items and the final design of the flowchart were prepared 
and finalised by the steering group based on the discussions at the Face-to-Face 
meeting. Subsequently, the steering group reviewed the guidelines and made minor 





Online Delphi process 
In total, 30 individuals agreed to participate in the online Delphi process and a 100% 
response rate was attained in rounds 1 and 2. Round 1 consisted of a PRIRATE 
checklist with 57 items and a PRIRATE flowchart. Of the 57 items, 55 were awarded 
a score between 7 and 9 by ≥70% of members and were therefore included in the 
PRIRATE checklist; however, consensus on two items was not achieved and these 
were subjected to further discussion. Thus, round 2 consisted of a PRIRATE checklist 
with these two items and the PRIRATE flowchart. Both items were awarded a score 
between 7 and 9 by ≥70% of members and they were included in the PRIRATE 
checklist. After analyzing individual comments received from the PDG, the flowchart 
was revised following round 1 and round 2. 
 
Face-to-Face meeting 
In total, four steering committee members (PD, VN, HD, LB) and 21 members 
attended the Face-to-Face meeting, which was chaired by two steering committee 
members (PD, HD). The PRIRATE checklist and flowchart were discussed to 
determine the views of members on whether the items should be included or 
excluded and whether the specific text for each item was clear and understandable, 
or needed modification. Several issues were raised during the meeting, which were 
discussed and after agreement was reached integrated into the appropriate items in 
the checklist. The flowchart was modified as a result of several constructive 




The steering committee revised the PRIRATE checklist and flowchart based the 
comments from the PFMG at the Face-to-Face meeting. The final checklist and 
flowchart were then piloted to ensure they could be used during the development of 
manuscripts reporting actual randomized clinical trials. The final PRIRATE 2020 
checklist comprises 11 sections (Title, Keywords, Abstract, Introduction, Methods, 
Results, Discussion, Conclusion, Funding details, Conflict of interest, Quality of 
images) with 58 individual items. Table 1 contains the PRIRATE 2020 checklist to be 
used when reporting randomized clinical trials in Endodontics. Figure 1 is the 
PRIRATE 2020 flowchart that summaries the various steps involved in reporting a 
randomized clinical trial and consists of 11 domains (Aim/objectives of the trial, 
Ethics, Number of subjects that were (i) Assessed for eligibility, (ii) Randomized, (iii) 
Allocated to intervention(s)/control, (iv) Received intervention(s)/control, (v) Lost 
to Follow-up, (vi) Analysed intervention(s)/control, Conclusion(s), Funding details 





Many reports of randomized clinical trials lack clarity, transparency and 
completeness (Moher et al. 2008, 2010a, b) and are rejected by journals, resulting in 
a waste of the time and resources that were spent on designing, conducting and 
reporting the research. Equally, if a poor-quality manuscript is published, readers are 
left with an incomplete or confused picture of what and how the research was carried 
out (Moher et al. 2010b), which can also cause confusion if others attempt to repeat 
the study. Furthermore, the publication of inaccurate or misleading findings has 
important consequences and risks for the clinical decisions that may be subsequently 
carried out (Sarkis-Onofre et al. 2015). Sarkis-Onofre et al. (2017) conducted a survey 
among the editors of dental journals on how they used reporting guidelines.  They 
emphasized that the use of reporting guidelines had resulted in an important positive 
impact in the development of oral health research and had improved the quality and 
transparency of papers published in dentistry. 
 
 The current study aimed to develop reporting guidelines, exclusively for 
randomized clinical trials in Endodontics. The PRIRATE 2020 guidelines are a set of 
items that are considered to be essential for authors to include when writing a 
randomized clinical trial for publication and consists of a checklist of 11 sections with 
58 individual items and a flowchart.  Each section of the PRIRATE 2020 checklist 
addresses individual components within a randomized trial, with several items 
within each. If implemented, the PRIRATE 2020 guidelines will aid researchers when 
designing, conducting and reporting randomized clinical trials as they provide a 
standardized and logical template. 
 
Illustrations are an effective and a rapid way to communicate information to 
readers. Indeed, some readers may only look at the figures without reading the main 
text of a manuscript. Relevant illustrations allow authors to support their findings, 
report their discovery, and have the potential to generate new research hypotheses 
(Kotz & Cals 2013, Polepalli Ramesh et al. 2015). Hence, due to the importance of 
images in many randomized clinical trials, particularly in Endodontics, several items 
relating to the quality of images were included in the PRIRATE 2020 checklist. The 
images in these guidelines refers to radiographs, CBCT/CT/MRI scans, histology 
slides, clinical photographs etc.  The section covering the quality of images in the 
checklist includes 9 items, which allows authors to provide essential information to 
explain fully the nature of the images and the information they convey. For clarity, it 
should be noted that some randomized clinical trials do not require images, e.g. 
clinical trials on the effectiveness of local anaesthetics or effectiveness of drugs 
assessing postoperative pain. 
 
A pictorial representation in a form of a flowchart helps readers obtain at a 
glance an overview of a randomized clinical trial; they also help authors when writing 
up a manuscript for publication. Egger et al. (2001) reported that CONSORT 
flowcharts were associated with improved reporting quality of randomized clinical 
trials. Hence, a flowchart has also been included in the PRIRATE guidelines. 
 
Parallel group randomized clinical trials are the most commonly used design 
(90 %) in Endodontics (Yi et al. 2020). The PRIRATE 2020 guidelines have focused to 
a large extent on parallel study designs. One of the possible limitations of the 
PRIRATE guidelines is that they are not so relevant for other randomised trial designs 
(e.g. cluster randomized or crossover trials). In the future, as the need arises, the 
PRIRATE steering committee will extend the main PRIRATE guidelines to include 




1. Explanation and elaboration document: The steering committee will prepare an 
explanation and elaboration document to outline the rationale and importance for 
each item in the checklist and for the flowchart. Additionally, each item and the 
flowchart will be supported and explained using suitable examples from the 
literature or hypothetical situations.  
 
2. Translation: The PRIRATE 2020 guidelines will be translated into various 
languages, to benefit authors across the globe.   
 
3. Dedicated website: The PRIRATE 2020 checklist and flow chart published in the 
International Endodontic Journal will be linked to a new dedicated website: Preferred 
Reporting Items for study Designs in Endodontology (PRIDE) (www.pride-
endodonticguidelines.org). The PRIRATE 2020 checklist and flow chart will be 
available and freely downloadable on the website. Academics, researchers, journal 
editors, clinicians and students will be able to provide their feedback on the PRIRATE 
guidelines via the PRIDE website, which will assist the steering committee when they 
are revised over time.  
 
4. Endorsement: The project leaders will contact the Editor-in-chief/Associate Editors 
of relevant Endodontology and other dental journals to seek their support in adopting 
the PRIRATE 2020 guidelines, by adding the website link for the guidelines in the 





The PRIRATE 2020 guidelines have been developed using a well-documented and 
validated consensus process that has resulted in a checklist of 58 items under 11 
sections and a flowchart, which can be used when reporting randomized clinical trial 
in Endodontics. The expectation is that the PRIRATE 2020 guidelines will help 
authors to produce high-quality reports of the randomized clinical trials they carry-
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Table 1: PRIRATE 2020 checklist of items to be included when reporting 
randomized trials in Endodontics. 
 




Table 1: PRIRATE 2020 checklist of items to be included when reporting 







Checklist Items Reported 
on page 
number 
Title 1a The phrase “Randomized clinical trial” or “Randomized controlled 
trial” must be included in the title 
 
1b Details of the specific area(s) of interest using words and phrases that 
identify the clinical problem and the intervention(s), must be 
provided 
 
Keywords 2a Keywords indicating the specific area(s) of interest using MeSH 
terms must be included 
 
Abstract 3a The Introduction of the Abstract must explain briefly the rationale for 
the trial 
 
3b The aim/objective(s) of the trial must be provided at the end of the 
Introduction section within the Abstract 
 
3c The Methodology section within the Abstract must provide essential 
information on the nature of the trial (e.g. superiority, non-
inferiority, equivalence), its design (e.g. parallel, split-mouth, 
crossover), the inclusion/ exclusion criteria, randomization process, 
blinding process and statistical analysis 
 
3d The Results section within the Abstract must describe the number of 
participants that were randomized and analyzed, the size and 
direction (group favoured) of the difference(s) between the 
intervention(s) and control groups with statistical analysis (p values 
and 95% CI). Adverse events or side-effects (if any) must also be 
reported or if none occurred, that must be mentioned explicitly 
 
3e The Conclusion section within the Abstract must summarise the 
findings and emphasise the clinical implication(s) of the results 
 
3f The prospective registration (number and name of the registry) and 
source(s) of funding must be provided 
 
Introduction 4a The scientific background and rationale for the trial must be 
provided, including the gap(s) or inconsistencies in knowledge 
 
4b The specific aim/objective (s) of the trial must be provided and the 
main clinical research question formulated clearly, preferably using 







Details of the nature of the trial (superiority, non-inferiority, 
equivalence of experimental intervention(s)), its design (parallel, 
split mouth, crossover, single/double blinded) and test:control 
allocation ratio must be provided. If applicable, important 
information about the study design must also be provided, e.g. 
pragmatic or preference trial, phase (drug trials), patient or public 
involvement in planning etc 
 
5b Changes to the methodology after the trial commenced (such as 




5c Details of the ethical approval of the protocol and the process for 
obtaining informed consent must be provided 
 
5d Details of the trial protocol including registration number and name 
of registry/clinical database and where it can be accessed (open 






5e A list of inclusion and exclusion criteria at the individual/tooth/root 
level must be provided 
 
5f Details of the setting/environment of the trial must be provided. 
Details on how many operators were involved in performing the 
intervention and control and their relevant experience/qualifications 
are essential. The setting where the data were collected must be 
described. If several operators are included and/or if it is a multi-
centre set-up, details of how standardization/calibration between 
individuals or centres was achieved must be provided 
 
5g The treatments in the intervention (experimental) group(s) must be 
described with sufficient detail to allow replication, including how 
and when they were actually administered 
 
5h The intervention(s) or absence of intervention(s) in the control 
group must be described with sufficient details to allow replication, 





5i The primary and secondary (if any) outcome measures must be 
described, including how and when they were assessed and by whom 
 
5j Details of any changes made to the study outcomes after the 
commencement of the trial must be described 
 
5k If primary or secondary outcomes are to be regarded as surrogate 
outcomes,  the rationale and empirical support for the connection 
between surrogate(s) and the outcome(s) of clinical relevance must 
be provided 
 
Sample size 5l How the sample size was determined must be described with 
reference to the published literature,  or a pilot study. The sample size 
 
may be modified after an internal feasibility study. Sample size 
calculations should generally refer to the primary outcome measure. 
If secondary outcome measures constitute the base for sample size 
calculation, an explanation must be provided 






5n The method used to generate the random allocation sequence along 
with any details of the type of restriction (e.g. blocking) if applicable 
must be described. The persons responsible for randomization and 
recruitment must be provided. For multi-centre trials a central 
randomization procedure is preferred and must be described. The 
unit of randomization should be specified and justified. Any 
stratification variables must be detailed 
 
5o Methods for allocation concealment up to the assignment of the 
participants into the intervention groups must be described 
 
Blinding  5p Information on who was/were blinded after assignment to the 
interventions (e.g. participants, care-givers, evaluators) must be 
described in detail. Blinding through masking of interventions (e.g. 
similar looking drugs/instruments) should be described. Detailed 




5q The statistical methods used for analysis of the primary and 
secondary (if any) outcomes, additional subgroup analyses and 
adjusted analyses (if applicable) must be described in detail. 
Consideration of drop-outs should be included in the calculations 
 





6a The number of participants who were randomly assigned, received 
the intended treatment, and were analysed for the primary and 
secondary (if any) outcome(s) for each group must be described. A 
flowchart must be provided 
 
6b Reasons for losses/drop-outs and exclusions after randomization 
must be described for each group and included in the flow chart. If 
intention to treat analyses are used, details of the process must be 
provided 
 
6c The dates of recruitment, follow-up and study duration must be 
described 
 
6d Reason(s) for any early termination of the trial must be described  
6e The baseline demographic and clinical characteristics of each group 
must be provided 
 
6f The results for each group for each primary and secondary (if any) 
outcome(s), along with the estimated effect size and its precision, 
must be provided    
 
6g Both absolute and relative effect sizes for binary outcomes must be 
provided 
 
6h The results from any other analyses performed must be described, 
including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
 
6i The incidence and management of any adverse effects or unintended 




7a An estimate of  the overall internal validity must be provided as well 
as the generalizability (external validity, applicability, real-world 
relevance) of the trial findings 
 
7b The rationale for inclusion, exclusion criteria and study duration 
must be provided 
 
7c An explanation of the clinical relevance of the primary and secondary 
outcomes must be provided 
 
7d A detailed interpretation consistent with results, balancing benefits 
and harms, and considering other relevant evidence must be 
provided 
 
7e The strength(s) of the trial must be provided  
7f The limitations of the study must be provided, addressing the sources 
of potential bias, imprecision and, if applicable, multiplicity of 
analyses 
 
7g Implication for future research and clinical practice must be 
described 
 
Conclusion 8a A rationale for the conclusion(s) must be provided, and the clinical 
significance highlighted 
 
8b Explicit conclusion(s) from the trial must be provided  
Funding 
details  
9a Sources of funding and other support (such as supply of drugs, 





10a An explicit statement on conflicts of interest must be provided  
11a Details of the equipment, software and settings used to acquire the 





11b The reason why the image(s) was acquired and the rationale for its 
inclusion in the manuscript must be provided in the text.  A 
justification for all images which involve radiation must be included 
 
11c The circumstances (conditions) under which the image(s) were 
viewed and evaluated by the authors must be provided in the text 
 
11d The resolution and any magnification of the image(s) or any 
modifications/enhancements (e.g. adjustments for brightness, colour 
balance, or magnification, image smoothing, staining etc) that were 
carried out must be described in the text or legend 
 
11e Patient(s) identifiers (names, patient numbers) must be removed to 
ensure they are anonymised 
 
11f An interpretation of the findings (meaning and implications) from 
the image (s) must be provided in the text  
 
11g The legend associated with each image must describe clearly what 
the subject is and what specific feature(s) it illustrates. Images of 
patients must describe the age, gender and ethnicity of the person, if 
relevant 
 
11h Markers/labels must be used to identify the key information in the 
image(s) and defined in the legend 
 
11i The legend of each image must include an explanation whether it is 
pre-treatment, intra-treatment or post-treatment and, if relevant, 
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